News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Discover Latest #Dinar News, Articles and Videos with Contenting
The Dinar is a currency that has been used in Iraq since 1932. It is currently the official currency of Iraq, and is used in many other countries in the Middle East. While it is a relatively stable currency, in recent years the value of the Dinar has fluctuated due to the instability in the region. This has led to speculation about the future of the currency, as well as a number of articles and videos discussing the currency. This section contains a collection of news, articles and videos about the Iraqi Dinar.
Bill Gates Once Had A 'Gaping Hole' In His Dashboard: Sequoia's Michael Moritz Recalls Being Chauffeured By A Future Billionaire Obsessed With A 7-Minute Commute While Building Microsoft - Microsoft (NASDAQ:MSFT) - Benzinga
Venture capitalist Michael Moritz of Sequoia Capital revealed an extraordinary anecdote about Microsoft Corp. co-founder Bill Gates that perfectly captures the obsessive focus that drove one of America's most successful tech entrepreneurs to billionaire status.
Datti Baba-Ahmed: opposition must 'do the unthinkable' to beat Tinubu - Businessday NG
Datti Baba-Ahmed, who ran as the Labour Party's vice-presidential candidate in 2023, has warned that Nigeria's opposition coalition needs to take extraordinary measures if they want to defeat President Bola Tinubu in 2027.
Cautionary Tales – Grand Theft Automated: How To Save A Trillion Lives | Tim Harford
A radical thought experiment transforms the lives of a new breed of philanthropists, as they follow the logic of altruism to extraordinary lengths. The most famous convert to the Effective Altruism movement, Sam Bankman-Fried, is either a humanitarian hero, or a con artist at an astonishing scale, or most bafflingly, both. [Apple] [Spotify] [Stitcher] Further reading The…
Man Group PLC : Form 8.3 - Deliveroo Plc - ForexTV
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeDeliveroo plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure03/07/2025(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”YES / NO / N/A 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security:0.5p ordinary InterestsShort positionsNumber%Number%(1) Relevant securities owned and/or controlled: (2) Cash-settled derivatives:15,291,4971.02 (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL:15,291,4971.02 All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors’ and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant securityPurchase/saleNumber of securitiesPrice per unit (b) Cash-settled derivative transactions Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit0.5p ordinaryEquity SwapIncreasing a long position25,8731.7630 GBP0.5p ordinaryEquity SwapIncreasing a long position259,1771.7630 GBP0.5p ordinaryEquity SwapIncreasing a long position14,8711.7630 GBP0.5p ordinaryEquity SwapIncreasing a long position2,6751.7630 GBP0.5p ordinaryEquity SwapIncreasing a long position88,5461.7630 GBP0.5p ordinaryEquity SwapIncreasing a long position5,1751.7630 GBP0.5p ordinaryEquity SwapIncreasing a long position49,9281.7630 GBP (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit (ii) Exercise Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable) 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”None (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none”None (c) Attachments Is a Supplemental Form 8 (Open Positions) attached?NO Date of disclosure:04/07/2025Contact name:James CarrTelephone number:+442071447242 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
WHEN LIGHT COMES UNEXPECTED: Clean Historical Fiction With Faith at the Center and Family at the Heart - ForexTV
Palmetto Publishing releases a delightful new addition to a Midwest pioneer fiction series, promising love, redemption, and warmth all around WHEN LIGHT COMES UNEXPECTED cover Charleston, SC, July 03, 2025 (GLOBE NEWSWIRE) -- Author John W. Vander Velden returns with the fourth installment of his heartfelt Misty Creek Saga—this time in a journey that spans the continent, from the fabled small town of Misty Creek to the nation’s Midwest. Set in the rugged beauty of 1890s America, When Light Comes Unexpected is an inspirational novel with a distinctly Christian heartbeat. Get ready for another extraordinary tale about the redemptive power of community. Readers of Misty Creek have fallen in love with the Sonnefelts, who have long accepted that they will never have children of their own. Now, Matthew and Elizabeth must embark on an adventure they never before thought possible, as they receive a letter calling them to travel to Illinois in order to reach three orphans looking for a home. Meanwhile, young Nick Coulter is left to manage the Misty Creek mill. His coming-of-age story is marked by new challenges, including vandalism, a personal rivalry, and a woman displaced from her home. Fans of the series will know—Nick understands the struggles of homelessness, and he will do anything in his power to help someone who faces them. As the Sonnefelts face legal complications with adopting the children, the oldest child, Lester, yearns to search for his father in Idaho, unconvinced that the man was truly lost in a mining accident. Can the new pair of parents use lessons learned from the hard years of Matthew’s youth and Elizabeth’s teaching experience to guide Lester and his sisters toward a bright future? Vander Velden’s writing lends a signature style that is rich with period details, emotional depth, and an undercurrent of faith and spiritual reflection. For fans of the Little House books and similar frontier America stories, it is the perfect read for middle-aged readers who want a safe, relaxing story free of explicit scenes or coarse language. When Light Comes Unexpected can be enjoyed with the previous books in the saga, but it functions equally well as a jumping-in point for new readers. Don’t miss this deep and meaningful exploration of what it takes for light to emerge in the darkest corners of our lives. When Light Comes Unexpected: Book Four of the Misty Creek Series is available for purchase online at Amazon.com and BarnesandNoble.com. For more information about the author, please visit any of his social media platforms. Facebook: John W. Vander Velden: Author (https://www.facebook.com/JohnWVanderVelden.Author/) Instagram: @john.vandervelden About the Author: John W. Vander Velden graduated from Purdue University and spent a long, rewarding career as a farmer. An avid reader and a lifelong storyteller, John is the author the Misty Creek series of novels and a literary blog, Ramblings . . . Essays and Such . . . He is an active member of the Plymouth Area Writer’s Workshop and has attended the Antioch Writer’s Workshop. John approaches life with open eyes, hearing ears, and a heart willing to feel, striving to reach deep within others with his words. He currently resides with his beloved wife in northern Indiana. To keep up with the latest on John’s projects, visit him online at johnvandervelden.com. Available for interviews: Author, John W. Vander Velden Attachment WHEN LIGHT COMES UNEXPECTED CONTACT: Leah Joseph Palmetto Publishing publicity@palmettopublishing.com
Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner - ForexTV
The expert jury selected Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D. of Araris Biotech, from a group of outstanding life science entrepreneursThe founding team is developing a breakthrough technology to establish a new generation of targeted cancer therapiesCommittee representatives presented the award and the EUR 100,000 cash prize on Thursday, July 3, 2025 Munich, Germany, July 04, 2025 – The Strüngmann Award selection committee today announced that Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., the founders of Araris Biotech, have been honored as this year’s winners. The award aims to support outstanding entrepreneurial and scientific achievements, as well as ground-breaking ideas in the life sciences industry. Araris Biotech’s founding team distinguished itself not only by developing of a novel technology in the antibody-drug conjugates (ADCs) field, but also by successfully validating this innovation through partnerships and a preclinical exit. This new drug class has the potential to significantly advance the development of targeted cancer therapies, thereby delivering added value for people living with cancer worldwide. “On behalf of the award committee and this year’s expert jury panel, we would like to congratulate Isabella Attinger-Toller, Dragan Grabulovski and Philipp Spycher. Together with the expert jury, we selected the founders of Araris Biotech as winners based on their combined leadership, entrepreneurial expertise and scientific excellence. Following the successful acquisition of Araris by Taiho Pharmaceuticals, we believe this award further recognizes the founding team’s continued growth and positive trajectory ahead. This trio has impressively demonstrated how a new idea, a clear focus on translation and entrepreneurial boldness can come together to launch a new generation of targeted cancer therapies,” said Andreas Strüngmann, M.D., and Thomas Strüngmann, Ph.D., in a joint statement. “It was a special privilege for us to engage with such a diverse, forward-looking group of start-ups from the DACH region. Learning more about the finalists and their impressive achievements made the final decision anything but easy.” The group of finalists selected in May comprised three companies: Araris Biotech, NovaGo Therapeutics and TOLREMO therapeutics, whose founders exemplify the entrepreneurial potential and scientific diversity that characterize the life sciences sector in the DACH region. They include an impressive variety of disciplines — spanning targeted cancer therapies, regenerative neuroscience and cancer drug resistance. Following the presentation of their entrepreneurial and scientific achievements to an expert jury, Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., were announced today as the winning team and will receive a joint cash prize of EUR 100,000. "We feel very honored to have our vision and achievements recognized by the Strüngmann Award. As the founding team, we have always believed in the potential of our new technology and the value it may hold for patients. This award, in addition to the acquisition by Taiho Pharmaceuticals, is a validation of our commitment, shared journey and the hard work that has enabled our success story," said Dragan Grabulovski, Ph.D., CEO of Araris Biotech, on behalf of the founding team. The Araris Biotech founders, the experienced biotech entrepreneur Dragan Grabulovski, Ph.D., (CEO), the visionary scientist Philipp Spycher, Ph.D., (CSO) and the outstanding translational scientist Isabella Attinger-Toller, Ph.D., (CTO), can look back on one of the most successful Swiss biotech startups to be established in recent years. Spun out of the Paul Scherrer Institute (part of ETH domain) in 2019, the team developed a novel ADC linker-payload technology (AraLinQ™) that enables one-step payload attachment to off-the-shelf antibodies, without the need for prior antibody engineering. This innovative approach not only opens new possibilities in oncology, but also has potential for applications in other therapeutic areas. In only a few years, the Araris team raised over CHF 40 million, formed a strategic partnership with Chugai (Roche) and Johnson & Johnson, and achieved a landmark acquisition by Taiho Pharmaceutical in March 2025 for up to USD $1.14 billion. Through these achievements, the three winners exemplify the potential within the DACH region to successfully translate scientific excellence into global innovation. About the Strüngmann AwardThe award was established in 2024 to recognize outstanding entrepreneurs realizing revolutionary ideas in the DACH life science sector. The goal is to reward exceptional achievements with a prestigious prize and to further the development of the next generation of leaders in this space. The award was named to honor twin brothers Andreas Strüngmann, M.D., and Thomas Strüngmann, Ph.D., who are among the important entrepreneurs, visionaries and investors in the life science sector. As the founders of Hexal, they achieved extraordinary entrepreneurial success and as investors, they have continued to repeat that success for more than 20 years by building and developing leading companies across the industry, including Mainz-based BioNTech. Learn more at https://struengmannaward.de/. About Araris Biotech AGAraris Biotech is a leading biotech company pioneering the future of antibody-drug conjugates (ADCs) and redefining the entire paradigm of targeted cancer therapy and beyond. Araris’ vision is a world without chemotherapy and its proprietary conjugation and groundbreaking multi-payload technology represents a quantum leap forward in ADC design, enabling the transformation of any antibody into an ADC with the goal of better safety and efficacy. By enabling the attachment of multiple, synergistic cancer-fighting payloads to a single antibody in an efficient one-step process, Araris is creating a new generation of smart missiles that deliver the potency of combination chemotherapy in a targeted fashion in order to tackle the persistent challenges of cancer resistance. Araris is a wholly owned subsidiary of Taiho Pharmaceutical following its acquisition in March 2025. For more information about our science and pipeline, please visit https://www.ararisbiotech.com/. Media ContactTrophic CommunicationsStephanie May, Ph.D. and Anja HeuerPhone: +49 (0) 171 185 56 82Email: athos@trophic.eu Attachment Strüngmann Award 2025 Goes To Araris Biotech
Stallion Uranium to Resume Trading on the TSX-V and Enters into Agreement to Sell Shares of 1503571 B.C. LTD. - ForexTV
VANCOUVER, British Columbia, July 04, 2025 (GLOBE NEWSWIRE) -- Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) is pleased to announce that, further to the Company’s news releases dated May 14th, 2025 and May 21st, 2025, the TSX Venture Exchange ("TSX-V") has approved the resumption of trading of the Company's common shares. Trading will recommence on the TSX-V effective at markets’ open on July 7th, 2025. The Company is also pleased to announce that, further to its news release of November 28th, 2024, it has entered into a binding heads of agreement (the “Heads of Agreement”) dated June 7th, 2025 amongst 1503571 B.C Ltd. (“150 BC”), the remaining common shareholders of 150 BC (the “Shareholders”) and Resolution Minerals Ltd. (“RML”), an ASX Listed Issuer, pursuant to which RML shall acquire all of the issued and outstanding shares of 150 BC. The approval follows the revocation of the previously announced Cease Trade Order (“CTO”) issued by the British Columbia Securities Commission on May 7th, 2025, as a result of the Company's failure to file its audited annual financial statements, accompanying management discussion and analysis and certifications for the financial year ended December 31st, 2024 (the "Annual Filings"). The CTO was issued under Multilateral Instrument 11-103 - Failure-To-File Cease Trade Orders In Multiple Jurisdictions and prohibits the trading or purchase by any person or company of any securities of the Company in each jurisdiction in Canada in which the Company is a reporting issuer for as long as the CTO remains in effect; however, the CTO provides an exception for beneficial securityholders of the Company who are not currently (and who were not as of May 7th, 2025) insiders or control persons of the Company who may sell securities of the Company if both of the following criteria are met: (a) the sale is made through a foreign organized regulated market, as defined in Section 1.1 of the universal market integrity rules of the Investment Industry Regulatory Organization of Canada; and (b) the sale is made through an investment dealer registered in a jurisdiction of Canada in accordance with applicable securities legislation. Further, the Company announces that Winning Media LLC of Huston, Texas, provided marketing services through one ticker tag article via the Globe and Mail for a one-day term on February 28th, 2024, in consideration of a payment of USD$3,500. The services are no longer in effect and were not reviewed nor approved by the TSX-V at the time the services were provided as required by the policies of the TSX-V. With stronger internal controls now in place, Stallion remains focused on unlocking the significant potential of its exploration portfolio in the prolific Athabasca Basin, recognized globally for its high-grade uranium deposits. The Company looks forward to providing further updates on its upcoming exploration activities in the near future. Agreement to Sell Shares of 1503571 B.C. LTD.: Pursuant to the Heads of Agreement, Stallion, along with the Shareholders have agreed to sell their common shares of 150 BC (the “150 BC Shares”) to RML (the “Transaction”). Stallion acquired its 11,111,111 150 BC Shares in connection with the optioning of the Horse Heaven Property, as described in its news release dated November 8th, 2024. In connection with the Transaction, RML shall make the following payments to the Shareholders, on a pro rata basis in proportion to their shareholdings in 150 BC: (i) an aggregate of 444,812,889 fully paid ordinary shares in the capital of RML (“Consideration Shares”); (ii) an aggregate of 222,406,445 options to acquire fully paid ordinary shares in the capital of RML exercisable at A$0.018 each on or before July 31st 2028 (“Consideration Options”); (iii) pay the Shareholders an initial aggregate cash payment of A$600,000 on completion of the Transaction (“Completion”); and (ii) a second aggregate cash payment of A$400,000 payable within nine months of Completion. Stallion’s pro rata interest in such consideration is anticipated to be: 59,466,963 Consideration Shares, 29,733,482 Consideration Options, and aggregate cash payments of A$145,033. The Consideration Shares shall be subject to contractual escrow whereby 25% shall be released on Completion, 25% on the three-month anniversary from Completion, 25% on the six-month anniversary from Completion, and the final 25% on the 12-month anniversary from Completion. The Transaction is subject to due diligence, RML shareholder approval, regulatory approvals, and other customary conditions to closing. There can be no guarantee that the Transaction will be completed as anticipated, or at all. RML and the Shareholders are arm’s length parties to Stallion. About Stallion Uranium Corp. Stallion Uranium is working to ‘Fuel the Future with Uranium’ through the exploration of roughly 1,700 sq/km in the Athabasca Basin, home to the largest high-grade uranium deposits in the world. The company, with JV partner Atha Energy holds the largest contiguous project in the Western Athabasca Basin adjacent to multiple high-grade discovery zones and deposits. Our leadership and advisory teams are comprised of uranium and precious metals exploration experts with the capital markets experience and the technical talent for acquiring and exploring early-stage properties. For more information visit stallionuranium.com. On Behalf of the Board of Stallion Uranium Corp. Matthew SchwabCEO and Director Corporate Office:700 - 838 West Hastings Street, Vancouver, British Columbia, V6C 0A6 T: 604-551-2360info@stallionuranium.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”) that relate to the Company’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this material change report should not be unduly relied upon. These statements speak only as of the date they are made. Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this presentation are expressly qualified in their entirety by this cautionary statement.